$CDXC
ChromaDex Corp.

2024 Q4 Form 10-Q Financial Statement

#000162828024044540 Filed on October 31, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $25.58M
YoY Change 31.21%
Cost Of Revenue $9.340M
YoY Change 24.1%
Gross Profit $16.24M
YoY Change 35.68%
Gross Profit Margin 63.49%
Selling, General & Admin $13.35M
YoY Change 12.4%
% of Gross Profit 82.19%
Research & Development $1.290M
YoY Change 3.95%
% of Gross Profit 7.94%
Depreciation & Amortization $202.0K
YoY Change -25.19%
% of Gross Profit 1.24%
Operating Expenses $14.64M
YoY Change 11.6%
Operating Profit $1.602M
YoY Change -239.67%
Interest Expense $276.0K
YoY Change 45.26%
% of Operating Profit 17.23%
Other Income/Expense, Net
YoY Change
Pretax Income $1.878M
YoY Change -295.63%
Income Tax
% Of Pretax Income
Net Earnings $1.878M
YoY Change -295.83%
Net Earnings / Revenue 7.34%
Basic Earnings Per Share $0.02
Diluted Earnings Per Share $0.02
COMMON SHARES
Basic Shares Outstanding 76.38M shares 75.93M shares
Diluted Shares Outstanding 77.77M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $32.25M
YoY Change 21.13%
Cash & Equivalents $32.20M
Short-Term Investments
Other Short-Term Assets $2.248M
YoY Change -3.52%
Inventory $10.54M
Prepaid Expenses
Receivables $7.096M
Other Receivables $2.000M
Total Short-Term Assets $52.13M
YoY Change 10.5%
LONG-TERM ASSETS
Property, Plant & Equipment $3.617M
YoY Change -31.75%
Goodwill
YoY Change
Intangibles $397.0K
YoY Change -28.08%
Long-Term Investments
YoY Change
Other Assets $374.0K
YoY Change -17.62%
Total Long-Term Assets $4.388M
YoY Change -30.37%
TOTAL ASSETS
Total Short-Term Assets $52.13M
Total Long-Term Assets $4.388M
Total Assets $56.52M
YoY Change 5.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.903M
YoY Change -24.95%
Accrued Expenses $9.592M
YoY Change 4.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $12.00K
YoY Change 20.0%
Total Short-Term Liabilities $17.70M
YoY Change -8.97%
LONG-TERM LIABILITIES
Long-Term Debt $2.000K
YoY Change -80.0%
Other Long-Term Liabilities $4.452M
YoY Change -33.75%
Total Long-Term Liabilities $4.454M
YoY Change -33.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.70M
Total Long-Term Liabilities $4.454M
Total Liabilities $22.15M
YoY Change -15.37%
SHAREHOLDERS EQUITY
Retained Earnings -$189.1M
YoY Change -0.78%
Common Stock $76.00K
YoY Change 1.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $34.37M
YoY Change
Total Liabilities & Shareholders Equity $56.52M
YoY Change 5.68%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $1.878M
YoY Change -295.83%
Depreciation, Depletion And Amortization $202.0K
YoY Change -25.19%
Cash From Operating Activities $3.495M
YoY Change 773.75%
INVESTING ACTIVITIES
Capital Expenditures $41.00K
YoY Change 36.67%
Acquisitions
YoY Change
Other Investing Activities $20.00K
YoY Change
Cash From Investing Activities -$21.00K
YoY Change 5.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.039M
YoY Change
NET CHANGE
Cash From Operating Activities 3.495M
Cash From Investing Activities -21.00K
Cash From Financing Activities 1.039M
Net Change In Cash 4.513M
YoY Change 1087.63%
FREE CASH FLOW
Cash From Operating Activities $3.495M
Capital Expenditures $41.00K
Free Cash Flow $3.454M
YoY Change 833.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Entity File Number
EntityFileNumber
001-37752
dei Entity Registrant Name
EntityRegistrantName
CHROMADEX CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address Address Line1
EntityAddressAddressLine1
10900 Wilshire Blvd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
dei Entity Address City Or Town
EntityAddressCityOrTown
Los Angeles
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90024
dei Local Phone Number
LocalPhoneNumber
388-6706
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
CDXC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
76383267 shares
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
152000 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
152000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32398000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27325000 usd
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
90000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
68000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
10544000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
14525000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
2096000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
2450000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
49534000 usd
CY2024Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1718000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
2137000 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
397000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
510000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1899000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
374000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
383000 usd
CY2024Q3 us-gaap Assets
Assets
56522000 usd
CY2023Q4 us-gaap Assets
Assets
54964000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6903000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10232000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9493000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
691000 usd
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
12000 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
11000 usd
CY2023Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
195000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20622000 usd
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2579000 usd
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3311000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1873000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2563000 usd
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
2000 usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
12000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
22153000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
74981000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
74981000 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
76000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
75000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
223389000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
218845000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-189089000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-190460000 usd
CY2024Q3 us-gaap Translation Adjustment Functional To Reporting Currency Net Of Tax
TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax
-7000 usd
CY2023Q4 us-gaap Translation Adjustment Functional To Reporting Currency Net Of Tax
TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax
-4000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
34369000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
28456000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56522000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54964000 usd
CY2024Q3 us-gaap Revenues
Revenues
25580000 usd
us-gaap Revenues
Revenues
70472000 usd
us-gaap Revenues
Revenues
62374000 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
9340000 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
7526000 usd
us-gaap Cost Of Revenue
CostOfRevenue
27083000 usd
us-gaap Cost Of Revenue
CostOfRevenue
24531000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
16240000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
11969000 usd
us-gaap Gross Profit
GrossProfit
43389000 usd
us-gaap Gross Profit
GrossProfit
37843000 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6035000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
20753000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
19918000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1241000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4701000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3799000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6304000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5840000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17320000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19557000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
13116000 usd
us-gaap Operating Expenses
OperatingExpenses
42774000 usd
us-gaap Operating Expenses
OperatingExpenses
43274000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1602000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1147000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
615000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5431000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
1878000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-959000 usd
us-gaap Net Income Loss
NetIncomeLoss
1371000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5052000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75050000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75588000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76804000 shares
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
30718000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5052000 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76804000 shares
CY2024Q3 cdcx Nonvested Shares Of Restricted Stock
NonvestedSharesOfRestrictedStock
167000 shares
cdcx Nonvested Shares Of Restricted Stock
NonvestedSharesOfRestrictedStock
177000 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001386570
dei City Area Code
CityAreaCode
310
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2400000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1008000 usd
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76027000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76027000 shares
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1290000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77768000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74938000 shares
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
735000 usd
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
152000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75588000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74938000 shares
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2940963
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7096000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5234000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9592000 usd
CY2024Q3 us-gaap Deferred Income Current
DeferredIncomeCurrent
184000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
1878000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
17699000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
26508000 usd
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7044000 usd
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
276000 usd
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
188000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
756000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
379000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1117000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1641000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2904000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-3000 usd
us-gaap Net Income Loss
NetIncomeLoss
1371000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
34369000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
28672000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3714000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
27308000 usd
us-gaap Net Income Loss
NetIncomeLoss
1371000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5052000 usd
us-gaap Depreciation
Depreciation
512000 usd
us-gaap Depreciation
Depreciation
693000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
113000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
119000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
501000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
520000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2904000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3714000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
19000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
5000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
59000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
945000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-62000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-60000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1921000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-3981000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2053000 usd
cdcx Implementation Costs For Cloud Computing Arrangement
ImplementationCostsForCloudComputingArrangement
0 usd
cdcx Implementation Costs For Cloud Computing Arrangement
ImplementationCostsForCloudComputingArrangement
60000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-312000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-767000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3329000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-481000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
99000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1856000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-732000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-149000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-14000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
35000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-373000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-454000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3526000 usd
cdcx Purchases Of Leasehold Improvements And Equipment
PurchasesOfLeaseholdImprovementsAndEquipment
94000 usd
cdcx Purchases Of Leasehold Improvements And Equipment
PurchasesOfLeaseholdImprovementsAndEquipment
127000 usd
cdcx Proceeds From The Sale Of Leasehold Improvements And Equipment Net
ProceedsFromTheSaleOfLeaseholdImprovementsAndEquipmentNet
5000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-74000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-122000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1641000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
11000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
9000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
14000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1621000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-14000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5073000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6332000 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
152000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
152000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27325000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20441000 usd
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
152000 usd
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
152000 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
152000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32398000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26773000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
358000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
508000 usd
us-gaap Net Income Loss
NetIncomeLoss
1400000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3500000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32200000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
1878000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-959000 usd
us-gaap Net Income Loss
NetIncomeLoss
1371000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5052000 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74938000 shares
CY2022 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2024#AccountingStandardsUpdate201613Member
CY2024Q3 us-gaap Assets Current
AssetsCurrent
52134000 usd
CY2023Q3 us-gaap Revenues
Revenues
19495000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
14638000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75972000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74938000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75050000 shares
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1043000 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-5000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
34369000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
27150000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
cdcx Proceeds From The Sale Of Leasehold Improvements And Equipment Net
ProceedsFromTheSaleOfLeaseholdImprovementsAndEquipmentNet
20000 usd
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
152000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-959000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
27308000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
28456000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-1907000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6468000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
152000 usd
us-gaap Nature Of Operations
NatureOfOperations
Nature of Business<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ChromaDex Corporation and its wholly owned subsidiaries, ChromaDex, Inc., ChromaDex International, Inc., ChromaDex Analytics, Inc., ChromaDex Asia Limited, Asia Pacific Scientific, Inc., ChromaDex Europa B.V. and ChromaDex Sağlik Ürünleri Anonim Şirketi (collectively, “ChromaDex” or the “Company”) are a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. NAD+ levels in humans have been shown to decline with age, among other factors, and may be increased through administration of NAD+ precursors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ChromaDex is the innovator behind the NAD+ precursor nicotinamide riboside chloride (“NRC”, commonly referred to as “NR”), commercialized as the flagship ingredient Niagen®, available in both food and pharmaceutical grades. Nicotinamide riboside chloride and other NAD+ precursors are protected by ChromaDex’s patent and/or licensed rights portfolio. The Company delivers food-grade Niagen® as the sole or principal dietary ingredient in its dietary supplement consumer product line, Tru Niagen®. As part of its consumer product offerings, the Company offers NAD+ test kits exclusively to healthcare practitioners. Furthermore, the Company develops and commercializes proprietary ingredient technologies, including food-grade Niagen® and pharmaceutical-grade Niagen®, and supplies these ingredients as raw materials to the manufacturers of consumer products and U.S. FDA-registered 503B outsourcing facilities, respectively. Additionally, the Company provides natural product fine chemicals, known as phytochemicals, and related research and development services.</span></div>
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75972000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75050000 shares
CY2024Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1796000 shares
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1216000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77768000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75050000 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
cdcx Nonvested Shares Of Restricted Stock
NonvestedSharesOfRestrictedStock
167000 shares
CY2023Q3 cdcx Nonvested Shares Of Restricted Stock
NonvestedSharesOfRestrictedStock
167000 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75972000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75050000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1216000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75050000 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 reportable_segment
CY2024Q3 us-gaap Revenues
Revenues
25580000 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
9340000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
16240000 usd
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7044000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1290000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6304000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
14638000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1602000 usd
CY2023Q3 us-gaap Revenues
Revenues
19495000 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
7526000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
11969000 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6035000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1241000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5840000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
13116000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1147000 usd
us-gaap Revenues
Revenues
70472000 usd
us-gaap Cost Of Revenue
CostOfRevenue
27083000 usd
us-gaap Gross Profit
GrossProfit
43389000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
20753000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17320000 usd
us-gaap Operating Expenses
OperatingExpenses
42774000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
615000 usd
us-gaap Revenues
Revenues
62374000 usd
us-gaap Cost Of Revenue
CostOfRevenue
24531000 usd
us-gaap Gross Profit
GrossProfit
37843000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
19918000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3799000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19557000 usd
us-gaap Operating Expenses
OperatingExpenses
43274000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5431000 usd
CY2024Q3 us-gaap Revenues
Revenues
25580000 usd
CY2023Q3 us-gaap Revenues
Revenues
19495000 usd
us-gaap Revenues
Revenues
70472000 usd
us-gaap Revenues
Revenues
62374000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 reportable_segment
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
9340000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
16240000 usd
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7044000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1290000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6304000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
14638000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1602000 usd
CY2023Q3 us-gaap Revenues
Revenues
19495000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
11969000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5840000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1147000 usd
us-gaap Revenues
Revenues
70472000 usd
us-gaap Cost Of Revenue
CostOfRevenue
27083000 usd
us-gaap Gross Profit
GrossProfit
43389000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
20753000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4701000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17320000 usd
us-gaap Operating Expenses
OperatingExpenses
42774000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
615000 usd
us-gaap Revenues
Revenues
62374000 usd
us-gaap Cost Of Revenue
CostOfRevenue
24531000 usd
us-gaap Gross Profit
GrossProfit
37843000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
19918000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3799000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19557000 usd
us-gaap Operating Expenses
OperatingExpenses
43274000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5431000 usd
CY2024Q3 us-gaap Revenues
Revenues
25580000 usd
CY2023Q3 us-gaap Revenues
Revenues
19495000 usd
us-gaap Revenues
Revenues
70472000 usd
us-gaap Revenues
Revenues
62374000 usd
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4765000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5962000 usd
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
2762000 usd
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
3537000 usd
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
2498000 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4478000 usd
CY2024Q3 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
519000 usd
CY2023Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
548000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
10544000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
14525000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1900000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2400000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2900000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3300000 usd
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4765000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5962000 usd
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
2762000 usd
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
3537000 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4478000 usd
CY2024Q3 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
519000 usd
CY2023Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
548000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
10544000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
14525000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1900000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2400000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2900000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3300000 usd
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
218000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
231000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
668000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
692000 usd
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
218000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
231000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
668000 usd
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
104000 usd
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
79000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
309000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
191000 usd
CY2024Q3 cdcx Total Operating Lease Expenses
TotalOperatingLeaseExpenses
322000 usd
CY2023Q3 cdcx Total Operating Lease Expenses
TotalOperatingLeaseExpenses
310000 usd
cdcx Total Operating Lease Expenses
TotalOperatingLeaseExpenses
977000 usd
cdcx Total Operating Lease Expenses
TotalOperatingLeaseExpenses
883000 usd
CY2024Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
4000 usd
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
4000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
12000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
12000 usd
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
326000 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
314000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
989000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
895000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.066
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
218000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1135000 usd
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
104000 usd
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
79000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
191000 usd
CY2024Q3 cdcx Total Operating Lease Expenses
TotalOperatingLeaseExpenses
322000 usd
CY2023Q3 cdcx Total Operating Lease Expenses
TotalOperatingLeaseExpenses
310000 usd
cdcx Total Operating Lease Expenses
TotalOperatingLeaseExpenses
977000 usd
cdcx Total Operating Lease Expenses
TotalOperatingLeaseExpenses
883000 usd
CY2024Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
4000 usd
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
4000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
12000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
12000 usd
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
326000 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
314000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
989000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.066
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
218000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1135000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
491000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
30000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3133000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
252000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2881000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1008000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1873000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y4M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.743
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.043
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
901000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
491000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
358000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
30000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3133000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
252000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2881000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1008000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1873000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y4M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.743
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.043
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q3 us-gaap Share Price
SharePrice
3.65
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1117000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2904000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3714000 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3800000 usd
us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
10100000 usd
CY2019Q3 us-gaap Accounts Receivable From Securitization
AccountsReceivableFromSecuritization
1600000 usd
CY2024Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
4800000 usd
CY2024Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
5200000 usd
CY2024Q3 us-gaap Share Price
SharePrice
3.65
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
735000 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1117000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2904000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3714000 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3800000 usd
us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
10100000 usd
CY2019Q3 us-gaap Accounts Receivable From Securitization
AccountsReceivableFromSecuritization
1600000 usd
CY2024Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
4800000 usd
CY2024Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
5200000 usd
CY2024Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
4750000 usd
CY2024Q3 us-gaap Purchase Obligation
PurchaseObligation
9965000 usd
CY2022Q3 cdcx Other Income Net Employee Retention Credit Cares Act
OtherIncomeNetEmployeeRetentionCreditCARESAct
2100000 usd
CY2023 cdcx Proceeds From Employee Retention Tax Credit Cares Act
ProceedsFromEmployeeRetentionTaxCreditCARESAct
900000 usd
CY2022 cdcx Proceeds From Employee Retention Tax Credit Cares Act
ProceedsFromEmployeeRetentionTaxCreditCARESAct
600000 usd
CY2024Q3 cdcx Prepaid Expenses And Other Current Assets Employee Retention Credit Cares Act
PrepaidExpensesAndOtherCurrentAssetsEmployeeRetentionCreditCARESAct
900000 usd
CY2024Q3 cdcx Accrued Expenses Employee Retention Credit Cares Act
AccruedExpensesEmployeeRetentionCreditCARESAct
100000 usd
CY2024Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
5215000 usd
CY2024Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
4750000 usd
CY2024Q3 us-gaap Purchase Obligation
PurchaseObligation
9965000 usd
CY2022Q3 cdcx Other Income Net Employee Retention Credit Cares Act
OtherIncomeNetEmployeeRetentionCreditCARESAct
2100000 usd
CY2023 cdcx Proceeds From Employee Retention Tax Credit Cares Act
ProceedsFromEmployeeRetentionTaxCreditCARESAct
900000 usd
CY2022 cdcx Proceeds From Employee Retention Tax Credit Cares Act
ProceedsFromEmployeeRetentionTaxCreditCARESAct
600000 usd
CY2024Q3 cdcx Prepaid Expenses And Other Current Assets Employee Retention Credit Cares Act
PrepaidExpensesAndOtherCurrentAssetsEmployeeRetentionCreditCARESAct
900000 usd
CY2024Q3 cdcx Accrued Expenses Employee Retention Credit Cares Act
AccruedExpensesEmployeeRetentionCreditCARESAct
100000 usd
CY2024Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
732000 usd
CY2024Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
732000 usd
CY2023Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
732000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
149000 usd
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2579000 usd
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3311000 usd
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
732000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
149000 usd
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2579000 usd
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3311000 usd
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
cdcx-20240930_cal.xml Edgar Link unprocessable
cdcx-20240930_htm.xml Edgar Link completed
0001628280-24-044540-index-headers.html Edgar Link pending
0001628280-24-044540-index.html Edgar Link pending
0001628280-24-044540.txt Edgar Link pending
0001628280-24-044540-xbrl.zip Edgar Link pending
cdcx-20240930.htm Edgar Link pending
cdcx-20240930.xsd Edgar Link pending
cdcx-20240930_g1.jpg Edgar Link pending
cdxcex-311q32024.htm Edgar Link pending
cdxcex-312q32024.htm Edgar Link pending
cdxcex-321q32024.htm Edgar Link pending
ex-102wrgracecotenthamendm.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
cdcx-20240930_def.xml Edgar Link unprocessable
cdcx-20240930_lab.xml Edgar Link unprocessable
cdcx-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending